On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Tuesday, June 12, 2012

SAS tips: converting the data between SAS data sets and Excel

›
Converting SAS data sets to Excel Book  In clinical trials, the database may be stored in SAS data set format. Sometimes, there is a need ...
9 comments:
Wednesday, June 06, 2012

Switching from non-inferiority to superiority - is multiplicity adjustment needed?

›
For a non-inferiority trial, after the non-inferiority is shown, one will typically try to show the non-inferiority. People may argue that ...
2 comments:
Saturday, May 26, 2012

SAS Resources on the Web

›
To be a good statistician, mastering the programming (SAS, SPSS, R, ...) is very important. This is especially true for statisticians who ar...
2 comments:
Sunday, May 20, 2012

Log(x+1) Data Transformation

›
When performing the data analysis, sometimes the data is skewed and not normal-distributed, and the data transformation is needed. W...
2 comments:
Sunday, May 06, 2012

Is Last Observation Carried Forward (LOCF) a dead approach to be used?

›
“To cope with situations where data collection is interrupted before the predetermined last evaluation timepoint, one widely used sing...
2 comments:
Saturday, April 28, 2012

Cookbook SAS Codes for Bioequivalence Test in 2x2x2 Crossover Design

›
In Clinical Pharmacology, inferential statistics is performed to show the bioequivalence in terms of the Area Under the Curve (AUC) and ...
6 comments:
Thursday, April 19, 2012

The "PATIENTS' FDA" Act - Sens. Richard Burr and Tom Coburn Introduce a New Plan to Reform the FDA

›
In my previous article " Should the design and conduct of clinical trials be simplified? ", I discussed several FDA guidance that...
Sunday, April 15, 2012

Should the design and conduct of clinical trials be simplified?

›
As mentioned in one of FDA’s guidance, “in the past two decades, the number and complexity of clinical trials have grown dramatically. These...
Sunday, March 11, 2012

Standardized study data for electronic submission - CDISC compliance

›
FDA has recently issued a series of draft guidance on “providing regulatory submission in electronic format”. The most recent one is about “...
2 comments:
Friday, March 09, 2012

Futility Analysis in Clinical Trials - Stop the trial for futility

›
A colleague of mine asked me to explain the concept of “futility analysis” using plain languages. The question is triggered by the recent n...
9 comments:
Sunday, February 12, 2012

How to interpret odds ratios that are smaller than 1?

›
Here is a question posted on the web about the interpretation of odds ratios that are less than 1. "I know that OR estimates= 1 mean th...
40 comments:
Sunday, February 05, 2012

Design and Analysis of Bioequivalence Studies for Highly Variable Drugs (HVD) or Highly Variable Drug Products (HVDP)

›
For bioequivalence studies, it is often for us to show the average bioequivalence by declaring the bioequivalence if the 90% confidence int...
1 comment:
Saturday, January 28, 2012

Recording the outcome for AE/SAE when multiple events contribute to Death

›
In clinical trials, death event may occur. According to CDISC CDASH standards , death should not be recorded as an adverse event (AE) or s...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.